4DMedical (ASX: 4DX) will lend its analytical software to industry partners working to advance lung disease therapies. US-based SMS Biotech will use the software for a trial of its stem cell therapy for COPD, while a multinational lung device developer will employ it for a clinical trial of an implantable device. These partnerships highlight the growing demand for 4DMedical’s lung imaging technology, which provides precise structural imaging and functional insights.
The Australian government recently cleared SMS Biotech’s stem cell therapy trial, to be conducted on COPD patients at Cabrini Health in Victoria. 4DMedical’s software will assess baseline lung health and track changes post-therapy. The undisclosed medical device developer will also use 4DMedical’s technology to enhance its evaluation process for clinical trial candidates, aiming to improve participant identification and track key respiratory metrics. Collaborations with global companies form an integral part of 4DMedical’s commercialization strategy.
Recent congressional testimony at the US House of Representatives Committee on Veterans’ Affairs also highlighted 4DMedical’s technology, emphasizing the need for faster, affordable, and less invasive ways to diagnose lung disease to improve health outcomes for veterans. 4DMedical has partnered with Philips to provide quantitative analysis of lung function in veterans, transforming standard CT imaging into a detailed four-dimensional image. This aids clinicians in assessing pulmonary function, achieving faster diagnoses, and performing less invasive procedures.
